secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALNYLAM PHARMACEUTICALS, INC. (ALNY)
CIK:        0001178670
Form:       8-K
Filed at:   2023-07-26T23:59:59+00:00
Accession:  0001193125-23-194715
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alnylam partners with Roche on zilebesiran; receives $310M upfront, up to $2.5B milestones
--------------------------------------------------------------------------------

- Upfront cash payment of $310 million; potential total deal value up to $2.8 billion including development, regulatory, and sales milestones.
- Alnylam and Roche to co-develop and co-commercialize zilebesiran in US (50/50 profit share); Roche gets exclusive ex-US rights with low double-digit royalties.
- Alnylam leads joint clinical development plan including cardiovascular outcomes trial; development costs split 40% Alnylam, 60% Roche.
- Zilebesiran is an investigational RNAi therapeutic for hypertension, currently in Phase 2; Phase 1 showed durable blood pressure reduction up to 6 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/0001193125-23-194715-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-194715

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer